Seres Therapeutics, Inc. (MCRB)
| Previous Close | 0.9600 |
| Open | 0.9400 |
| Bid | 0.9554 x 300 |
| Ask | 1.0100 x 200 |
| Day's Range | 0.9145 - 1.0000 |
| 52 Week Range | 0.5400 - 2.9900 |
| Volume | |
| Avg. Volume | 3,751,346 |
| Market Cap | 148.633M |
| Beta (5Y Monthly) | 2.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1900 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.34 |
GlobeNewswireSeres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m. ET. A video webcast of the presentation will be available under the “Events and Presentations” tab on the “Investors and News” section of Seres
- GlobeNewswire
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated safety profile and confirmed drug bacteria strain engraftment; no treatment-related serious adverse events Company to seek Breakthrough Therapy designation from the FDA, given the high unmet medical need associate
ZacksAfter Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
